Navigation Links
Annual General Meeting Schedules, New Drug Applications, Positive Study Results, Conference Participations, and Secondary Offerings - Research Report on Mindray, AcelRx, Merrimack, ZELTIQ, and Clovis
Date:12/5/2013

NEW YORK, December 5, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Mindray Medical International Limited (NYSE: MR), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), ZELTIQ Aesthetics, Inc. (NASDAQ: ZLTQ), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Mindray Medical International Limited Research Report

On November 26, 2013, Mindray Medical International Limited (Mindray) announced that it will host its 2013 annual general meeting of record at the Company's Hong Kong office on December 17, 2013 at 11:00 a.m. Beijing/Hong Kong Time (December 16, 2013 at 10:00 p.m. US ET). Mindray reported that the shareholder record date is November 12, 2013. In addition, Mindray informed that its Form 20-F and proxy materials are accessible through the Investor Relations website. The Full Research Report on Mindray Medical International Limited - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/8d4d_MR

--

AcelRx Pharmaceuticals, Inc. Research Report

On December 2, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced that it
'/>"/>

SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
2. Omeros to Present at Oppenheimer 24th Annual Healthcare Conference
3. Neurocrine Biosciences To Present At Oppenheimers 24th Annual Healthcare Conference
4. Eisai Oncology to Present New Research on Eribulin and NEPA at 36th Annual San Antonio Breast Cancer Symposium
5. RheumatologyNetwork Presents RA Findings from ACR Annual Meeting
6. Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto
7. Agility-PSR Wins "Best Contract Research Organization" in the 2013 ROAR Awards at the 4th Annual World Orphan Drug Conference in Geneva
8. Isis Pharmaceuticals to Present at the Oppenheimer 24th Annual Healthcare Conference
9. MultiVu Video Feed: New Medical Studies From The 2013 RSNA Annual Meeting
10. Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
11. Nora Therapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
(Date:7/9/2014)... Small print and poor printing on prescription labels ... may lead to errors in taking medication, according ... and CNIB (Canadian National Institute for the Blind)., ... Pharmacists Journal , found that labels on prescription ... professionally recommended guidelines for legibility. , By simply ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2
... PROVIDENCE, RI The Miriam Hospital received three of ... of Health (NIH) aimed at improving HIV prevention and ... to only a handful of institutions nationwide, are part ... Criminal Justice System NIH,s largest research initiative to ...
... who have hypertension are much more likely to have ... to a new University of Rochester Medical Center (URMC) ... . In fact, when variables such as socio-economic levels ... more likely to have cognitive problems. ...
... HealthDay Reporter , MONDAY, Nov. 8 (HealthDay News) -- New ... smoked may be a different disease than it is in ... cancer tumors in 30 people who never smoked to tumors ... people who had never smoked had twice as many DNA ...
... have found a new pathway for repairing DNA damaged by ... journal Proceedings of the National Academy of Sciences . ... repair oxidative damage," said Peter Beal, professor of chemistry at ... part of its inflammatory response, the body,s immune system produces ...
... November 2010) Results from a European Observational ... today at the Tenth International Congress on Drug ... rate of discontinuation and sustained virologic suppression with ... up to five years. 1 The ...
... OAK BROOK, Ill. Multidetector computed tomography (CT) helps ... type of stroke, potentially speeding the delivery of life-saving ... the January issue of Radiology . ... first-line imaging tool for identifying the cause of acute ...
Cached Medicine News:Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 2Health News:Miriam receives $1.5 million from NIH to 'seek, test and treat' inmates with HIV 3Health News:Children with high blood pressure more likely to have learning disabilities 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 2Health News:Lung Cancer in Smokers, Nonsmokers May Be a Different Disease 3Health News:New DNA repair pathway 2Health News:Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients 2Health News:Using CT, radiologists can pinpoint cause of some strokes 2